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The alternatives to whole-animal testing include endpoint assays, cell and tissue cultures, use of tissue 
slices, toxicokinetic modelling, and structure-activity relationships and databases. The use of in vitro 
systems (subcellular fractions, cell lines, primary cell cultures, tissue slices, organ cultures, etc.) as 
research tools in toxicology is widespread. In the past few years, the apoptosis phenomena were followed 
by very precise intracellular changes where, through programmed cell death, a cell can be removed 
from a population. The in vitro systems are ideally suited for investigations of the molecular, cellular and 
physiological mechanisms of chemically induced toxicity, which cannot readily be studied in vivo for 
known target organ and target species toxicity studies and for answering specific questions about toxic 
effects. The main justification for developing in vitro toxicity tests is that they will make toxicology a more 
scientifically based practice. It is increasingly apparent that the development and incorporation of stepwise 
testing strategies, combining experimental data from a range of alternative methods (physicochemical 
techniques, quantitative structure-activity relationships - QSAR, metabolic and kinetic modelling and in
vitro tests), provide the most advanced way to predict toxicity, reducing at the same time the number of 
laboratory animals used for testing.
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Technical improvements in tissue culture and 
development of the Ames test, which uses bacteria 
to detect mutagens, challenge the view that animal 
testing is the only option in toxicity testing. In addition, 
there has been a growing recognition of the limitations 
of certain standard in vivo testing procedures. The 
explosion of knowledge in molecular biology has also 
significantly affected toxicology. Moreover, the costs 
of assessing potential health effects of some 200,000 
substances per year that are newly identified or 
synthesized necessitate alternatives to animal testing. 
It has been estimated that the cost of testing of a single 
substance using whole animals is frequently in excess 
of $2 million. In addition, the in vitro testing provides 
the researcher with considerably more control of the 
variables than the whole-animal testing. However, new 
tools for toxicity testing must be looked on as adjuncts 
to traditional testing methods. Any testing method has 
inherent difficulties; when using whole animals, data 
must be extrapolated from one species to another, 
and when using cell or tissue culture, data must be 
extrapolated to the whole animal.
The new testing methods that more accurately 
assess hazards, are less expensive and are able to 
determine toxicity more rapidly. It is the pursuit of 
these goals that accounts for the great progress in 
the alternative testing techniques. At the same time, 
certain basic tests, such as the Ames test, continue to 
be the workhorses for specific areas of toxicology.
The alternatives to whole-animal testing include 
endpoint assays, cell and tissue cultures, use of tissue 
slices, toxicokinetic modelling, and structure-activity 
relationships and databases. Some examples of non-
whole animal methods include the use of bacteria 
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and yeast to assess mutagenicity, chicken embryos 
to assess teratogenicity and fixed enzyme systems 
to screen for biological effects. The main questions 
concerning the use of alternatives are:
• How do we extrapolate from an in vitro system to 
an in vivo system (i.e., How do we relate effects 
in single cells to complex interactions in whole 
animals)?
• How do we use available in vitro and in vivo data 
to design better experimental approaches?
• How do we predict potential biological effects 
from the chemical structure of a substance?
The concordance between results from alternative 
tests and those from mammals is an important issue 
in protecting public safety. It is also important to 
note that the research using cells, tissue cultures 
or non-mammalian systems is conducted not only 
as an alternative to using mammals, but because a 
given alternative system provides the best answers to 
the question under study. The in vitro studies also 
allow researchers to understand the discrete steps in 
a specific sequence of events, which is difficult to do 
in whole animals.
One reason why cell and tissue culture systems are 
valuable in toxicity testing is that they can be observed 
with a light microscope while various components 
of the system are manipulated. For instance, one 
can observe the beating of cultured heart cells and 
note those effects of adding various chemicals to the 
culture medium. The human oral fibroblasts are used 
for testing dental materials, and the cell mats have 
been used for screening human tumours for sensitivity 
to anticancer drugs.
The use of in vitro systems (subcellular fractions, 
cell lines, primary cell cultures, tissue slices, organ 
cultures, etc.) as research tools in toxicology is 
widespread (1). In the past few years the apoptosis 
phenomena are followed by very precise intracellular 
changes, where through programmed cell death, 
a cell can be removed from a population. This 
regulated physiological process is followed by DNA 
fragmentation, nuclear blebbing, and cell shrinkage 
or by a number of marker enzymes. The molecular 
pathways that regulate apoptosis provide a possible 
target for oxidative damage, suggesting a role for 
transcriptional regulation of genes implicated in cell 
survival. Cells and tissues are subjected to oxidative 
stress when the concentration of reactive oxygen 
species (ROS) exceeds the antioxidant capability of 
the cell. The ROS levels can be modulated by changes 
in endogenous cytochrome P450s or exogenously 
following the administration of drugs, hormones, 
xenobiotics or toxicants.
In recent years there has also been a move toward 
standardizing the various techniques and procedures 
available, with the concomitant development and 
evaluation of numerous in vitro tests which have been 
proposed as potential replacements for various animal 
tests currently required by regulatory authorities (2, 3). 
There are four main factors driving the development 
of in vitro toxicology (4):
• the need for relatively simple, inexpensive and 
efficient systems for testing large number of 
chemicals for which the toxicological data are 
required,
• public and legislative pressures to reduce animal 
experimentation,
• the need for a better understanding of the 
mechanisms of chemical-induced toxicity, in 
order to improve the scientific basis of current 
risk assessment procedures, and
• the desire to use human cells and tissues 
whenever possible, for example to undertake 
inter-species comparisons of xenobiotic 
metabolism and toxicity.
VALIDATION OF TOXICITY TEST 
PROCEDURES
Validation is the process by which the reliability 
and relevance of a test method are evaluated for the 
purpose of supporting a specific use. The approaches 
and methods conform to scientific principles of 
objectivity and appropriate experimental design.
A test is considered validated when its performance 
characteristics, advantages and limitations have 
been adequately determined for a specific purpose. 
The measurement of a test reliability and relevance 
are independent stages in the validation of the test 
method, and both are required. Reliability is an 
objective measure of an intra- and interlaboratory 
reproducibility of the method. If the test is not 
sufficiently reliable, it cannot be used for its intended 
purpose. Alternatively, if the test is not relevant, or is 
of a questionable relevance to the biological effect of 
interest, or if it is not an appropriate measure of the 
effect, its reliability is academic. The relevance of the 
test may be linked to the mechanism of the toxic effect 
it measures and to its proposed uses. The measures 
of relevance of the test include the calculated 
Kniewald J, et al. ALTERNATIVES FOR TOXICITY TESTING
Arh Hig Rada Toksikol 2005;56:195-204
197
operational characteristics (e.g., sensitivity, specificity, 
etc) or statistically derived correlation coefficients and 
determinations of the mechanistic association of the 
measured effects with the toxic events of interest.
There are no optimum or minimum levels of 
reproducibility or association with the event of interest 
that must be reached for the test to be considered 
"validated". The conditions under which the test will 
be used and the purposes to which its results will 
be applied will determine the levels of reliability and 
relevance that are needed.
The new tests can be designed either as substitutes 
to replace, or to be interchangeable with, currently 
accepted tests, or as tests that have no correlate 
with currently used tests or endpoints. "Definitive 
tests" provide data that are used to measure toxic 
effects or unequivocally identify the hazardous 
substances and asses the risks posed by exposure 
to them. "Screening methods" are generally used 
to make preliminary hazard decisions (i.e., identify 
potential adverse effects), or to select chemicals or 
set priorities for other, more definitive tests. They 
often provide only a qualitative or semi-quantitative 
response and are generally not designed to serve as 
definitive tests. In contrast, "adjunct tests" are used to 
increase information base and/or aid the interpretation 
of results from other, definitive methods. They are 
not used in isolation or as substitutes for definitive 
methods, but they often support the relevance of 
the definitive test method by providing information 
related to the mechanism of toxicity. For example, 
a test showing that relevant metabolic pathways are 
similar in the test system and in the species of interest 
supports the use of information from the definitive 
test system for hazard and risk assessments. These 
tests can be developed for newly identified endpoints 
or effects, or they can be used to replace existing 
adjunct methods (5).
Because the data from a substitute test will be used 
in lieu of a currently used test, its adoption requires 
evidence from validation studies that the use of the 
method will provide a comparable or better level of 
protection of human health or of the environment 
than the current methods or approaches. Often, 
new tests are developed that identify or provide data 
about toxicological effects not addressed by existing 
methods. These new tests should be based on 
specific biological mechanisms or enpoints related 
to an effect of concern. The test itself often will help 
define the effect. When a new method is designed to 
measure an effect that is newly discovered or not well 
defined, there usually is no benchmark against which 
the usefulness or effectiveness of such a method can 
be judged.
Methods may be designed to stand alone, or as 
components of tiers, batteries, or hierarchical testing 
strategies, e.g. stepwise sequence of tests from simple 
to more complex ones. The process is leading to the 
scientific validation of stand-alone tests, or tests that 
are used only as a component of a test.
Validation is a scientific process designed 
to characterize the operational characteristics, 
advantages, and limitations of a test method, and 
to demonstrate its reliability and relevance. The 
designation of a test as "validated" or "not validated" 
for a specific purpose is not irrevocable; subsequent 
data and experience with the test can lead to a 
loss or affirmation of its validation status. Also, the 
test method could be considered validated for a 
specific use, but not for other uses. The criteria for 
validation of the test method are the function of 
the purpose for which the test method will be used. 
For example, the mechanisms of some effects are 
known or are relatively straightforward (e.g., skin 
corrosivity, estrogen receptor binding), while others 
(e.g., carcinogenicity, developmental toxicity) are 
complex and multi-faceted, or not well understood. 
The validation of tests for these different types of 
effects requires different approaches (6).
Critical to the validation process are the standardized 
test protocol and the ability of component laboratories 
to perform the test. "Prevalidation" is the process 
by which testing laboratories are selected and 
demonstrate competence in performing the testing 
procedures, and during which the test protocols are 
standardized. If a protocol cannot be standardized 
or reproduced using known chemicals, it cannot be 
validated.
A prerequisite for the performance and evaluation 
of any validation study is a formal protocol or 
procedural manual that can be readily understood 
and followed by individuals in other laboratories, and 
by administrative and scientific review personnel. 
This protocol should clearly state the purpose of the 
test. All test responses, regardless of whether they 
are in humans, animals, or cultured cells, contain a 
certain level of between-animal or between-culture 
variability, which may or may not be defined, that 
must be considered when evaluating the performance 
of the candidate method. Generally, the variability 
of in vivo methods is greater than that of in vitro 
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methods because of the wider degree of genetic and 
physiological diversity among whole animals.
When evaluating a new method, there must be 
a sufficient number of chemicals to demonstrate 
the test's performance within a chemical class or 
among a range of chemical classes or products 
and among substances of different reactivities. 
Other considerations are the cost and complexity 
of the method; for example, an in vitro test to 
identify oestrogen receptor-binding chemicals would 
require less time and resources to perform than an 
in vivo rodent reproductive test. These cost and 
time considerations would determine the numbers 
of chemicals that could reasonably be tested in a 
validation exercise.
In summary, the specific goals of the validation 
study and the hypotheses to be tested must be 
clearly defined. The test method must be shown to 
be reproducible and understandable in the context 
of science and, for substitute tests, the procedure 
should offer an advantage over the currently accepted 
procedures. Because tests can be designed and used 
for different purposes (e.g., as substitutes or screens) 
by different organizations, and with varying categories 
of substances, the test validation process should be 
highly flexible and adapted to the specific test and 
its proposed use. Despite this need for flexibility, all 
the various factors that make up a validation process 
must be included.
ALTERNATIVE METHODS DATABASES
It is a fundamental requirement that any scientist 
who intends to start a new project is well-informed 
about the current status of the proposed field of 
investigation. The animals should only be used in 
a study if such use is justifiable after all possible 
alternatives have been identified and found to be 
inadequate. Ready access to relevant information on 
the proposed topic of study can prevent unnecessary 
duplication of work, thereby contributing to a 
reduction in animal use.
The bibliographic and factual databases can 
be a powerful information tool, and the database 
searches are an essential part of a stepwise approach 
to toxicity testing. The field of toxicology is, in fact, 
an area of continuous investigation with respect 
to the identification of new directions in database 
development for the storage and dissemination of 
toxicological information.
There are many web sites that mention the 
alternatives only briefly as part of the scope of laboratory 
animal care. However, few are devoted exclusively to 
the alternative concept. For the researcher, educator 
or student in search of information on the alternatives, 
wandering from site to site for the best full-text 
information can be a challenge. The list of some web 
sites that follows emphasizes the alternatives and the 
sites that provide unique information developed by 
the host institution (7-9).
• Alternatives to Skin Irritation Testing in 
Animals, Toxicology Consulting Services, 
Plainsboro, USA; http://www.invitroderm.com. 
This non-profit web site is developed to display 
information about alternatives to skin irritation 
testing in animals.
• Altweb, John Hopkins Center for Alternatives 
to Animal Testing (CAAT), Baltimore, USA; 
http://caat.jhsph.edu. This is very extensive site 
for news, information, discussion and resources 
from the field of alternatives to animal testing.
• Animal Welfare Information Center (AWIC), 
Beltsville, USA; http://www.nal.usda.gov/awic. 
The AWIC was established in 1985 as part of 
an amendment to the Animal Welfare Act. The 
AWIC's mission is to provide training about more 
humane animal care and use for the researchers, 
who use animals, and to provide information 
for improving methods of the experimentation 
on animals that can reduce or replace the 
use of animals or minimize pain or distress to 
animals.
• Center for Alternatives to Animal Testing 
(CAAT), Baltimore, USA; http://caat.jhsph.edu. 
The CAAT was founded in 1981 as a resource 
of alternatives and a granting organization. It has 
created and maintained the Altweb site.
• European Centre for Validation of Alternative 
Methods (ECVAM ), Ispra, Italy; http://ecvam.
jrc.cec.eu.int/index.htm. The ECVAM was 
established in 1993, and was created to play 
a leading role at the European level in the 
independent evaluation of the relevance and 
reliability of tests and test strategies for specific 
purposes.
• Fund for the Replacement of Animals in Medical 
Experiments (FRAME), Nottingham, The 
United Kingdom; http://www.frame-uk.demon.
co.uk. The FRAME is founded in 1969, and is 
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charitable trust that advocates the 3 Rs approach 
(reducement, replacement, refinement) by 
encouraging realistic consideration of ethical 
and scientific issues. The FRAME web site 
provides an original section on searching for 
alternatives.
• Interagency Coordinating Committee for the 
Validation of Alternative Methods (ICCVAM), 
Research Triangle Park, USA; http://iccvam.
niehs.nih.gov. The ICCVAM coordinates 
development, validation, acceptance, and 
harmonization of alternative toxicological test 
methods to improve toxicity characterization, 
increase savings in time and cost, and implement 
the 3 Rs. The web site includes full texts of 
current ICCVAM reports, meeting proceedings, 
information about testing method development 
and methods under review.
• Information on Alternative Databases; http://
oslovet.veths.no/databasesintro.htlm. This 
collection links to more than 20 databases.
ALTERNATIVE APPROACHES FOR PREDICTING 
TOXIC HAZARD
The scientific and regulatory acceptance of 
alternative methods are of importance to promote 
the 3 Rs (reduce, refine or replace) on the use of 
laboratory animals. One of the main priorities was the 
implementation of procedures, which would enable it 
to become well-informed about the state-of-the-art of 
non-animal test development and validation, and the 
potential for the possible incorporation of alternative 
tests into regulatory procedures (10).
Quantitative Structure-Activity Relationships 
(QSAR) might be used in the design, evaluation and 
validation of in vitro tests and in the selection of 
appropriate test chemicals for validation studies. The 
principles underlying the development of QSARs are 
based on the premise that the properties of a chemical 
are implicit in its molecular structure. Therefore it 
follows that, if the mechanism for the activity of a 
group of chemicals can be elucidated, and relevant 
parameters can be measured or calculated, then, 
theoretically, a QSAR can be established. For the 
QSAR to be valid and reliable, the activities of all the 
chemicals covered must be elicited by a mechanism, 
which is both common and relevant. Attempts to 
derive QSARs for data sets where this is not the case 
have not always been successful. The same principles 
need to be applied to the development of in vitro 
toxicity tests. However, in many cases, such principles 
are overlooked. As a result, some alternative tests 
predict endpoints which are different from those which 
they claim to predict (because the wrong mechanism 
has been identified) or they cannot predict endpoints 
accurately for all classes of chemicals (because a 
common mechanism is lacking).
In terms of developing integrated approaches 
to the use of alternative methods for the prediction 
of toxic hazard, it is important to consider how 
the QSARs, computer modelling techniques (for 
example, physiologically based pharmacokinetic 
/PBPK/ models) and in vitro methods might be used 
in combination (11).
The QSAR is a model which relates the biological 
activities of a series of similar compounds to one or 
more (physico)chemical or structural properties of the 
compounds. In this definition, "similar" means having 
the same mechanism of action, but not necessarily 
having a related chemical structure. However, it is 
often difficult (if not impossible) to determine the 
mechanism of action, whereas it is usually less difficult 
to establish chemical similarity. Hence, the QSARs 
are generally developed for sets of chemically similar 
compounds (congeneric series), hoping that they 
will also have the same mechanism of action. Any 
compounds which do not act by the same mechanism 
are likely to fit the correlation only poorly and to appear 
as "outliers".
When a chemical is administered to an organism, 
two events must occur for a biological response to be 
triggered. Firstly, the compound has to be transported 
to the site of action (the "receptor") and, secondly, 
it must interact with the target in an appropriate 
manner. The interaction with the target (receptor) is 
governed largely by two factors: the size and shape 
of the xenobiotic, which will control how well the 
molecule fits the receptor site and the nature and 
relative positions of appropriate functional groups on 
the molecule, which will affect the type and strength 
of the interaction with complementary groups on the 
receptor. Many physicochemical properties can be 
used to model receptor interaction (12).
It is important to note that, in effect, the QSAR 
is concerned with the change in biological activity 
brought about by a change in chemical structure. 
But, there are a number of caveats to the use of the 
QSARs, therefore they have to be borne in mind, 
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otherwise the application of the QSARs may not be 
valid. Some of them are:
• The QSARs can be applied currently only to pure 
compounds. There are yet no firm guidelines for 
the use of mixtures in this respect.
• The set of compounds used to derive the 
QSAR (training set) should be selected from 
knowledge, or assumption, of a common 
mechanism of action.
• If possible, the QSAR parameters should 
be selected on the basis of mechanistic 
considerations. Alternatively, they should be 
amenable to mechanistic interpretation.
• For comparative purposes, concentrations or 
doses must be in molar, not weight, units.
• Each QSAR should be validated by investigating 
its predictive ability using a different set of 
compounds (test set), which could cover the 
same ranges of parameter space.
• The QSAR must not be applied outside of its 
domain of validity (i.e. outside of the parameter 
space covered by the training set).
Future requirements for the development of in 
vitro tests include more attention being focused on the 
elucidation of mechanisms of toxicity in vivo, the use 
of the QSARs in the rational selection of test chemicals 
for the development of integrated testing strategies 
which combine information on toxicological effects 
from different sources, including human studies where 
appropriate (13).
What are the ways of achieving a better integration 
of the QSAR and in vitro methods? The in vitro 
tests fall into three categories: empirical – those for 
which no clear mechanistic basis can be identified; 
mechanistic – those with a clear mechanistic basis; 
and analogous – those in which the in vivo test system 
is essentially reproduced in vitro. The QSAR methods 
may help to identify the mechanisms operating in in
vitro assays. These mechanisms should be defined 
in operational terms, i.e. in terms of the level of 
organisation (molecular, cellular, tissue, organ, whole 
organism) at which they are working in the animal. 
From this information it should be possible to judge 
the "mechanistic relevance" of the in vitro test.
The results from appropriate in vitro tests may 
also be used as molecular descriptors to develop the 
QSAR equations. For example, the in vitro cytotoxicity 
data can be used to model a toxic endpoint at the 
level of the whole organ. Although data from in 
vitro tests can be used to construct QSARs, it is 
also important to use existing animal data where 
available; the predictions obtained from such QSARs 
could then be used to improve the in vitro tests via 
definition of relevant mechanisms. A single QSAR or 
in vitro test cannot be used directly to extrapolate 
from one level of organisation to another. However, 
the families of QSARs or in vitro tests may be used to 
define rate-limiting parameters, which govern effects 
at different levels; for example, to relate the inhibition 
of acetylcholinesterase activity to lethality in the whole 
organism.
Current attempts to validate in vitro methods as 
alternatives to animal tests are based on the premise 
that in vitro potency can be related directly to in vivo 
potency. However, it is of fundamental importance to 
recognize the general inapplicability of this premise, 
since the relationships between in vitro and in 
vivo potencies can be expressed only in terms of 
probabilities. The practical significance of this for 
the validation of alternative methods is that, in the 
absence of a clear mechanistic relationship between 
in vitro and in vivo potencies, such validation must 
proceed in two stages:
• Stage 1: establishment of a general statistical 
relationship between the responses in the in vitro 
and in vivo tests. This stage must be performed 
using a wide range of chemicals, with different 
physicochemical properties, acting via different 
mechanisms of toxicity.
• Stage 2: establishment of a specific relationship 
between the in vitro and in vivo responses 
using separate models for each chemical class, 
which is defined by a common mechanism of 
toxicity.
It follows that, where a clear mechanistic 
relationship between in vitro and in vivo potencies 
has already been established, validation can begin 
in stage 2.
Generally, it is recommended that (14):
• The development of integrated testing strategies 
for predicting the systemic toxicity of chemicals 
should be given greater priority, due to animal 
welfare and economic considerations.
• The most appropriate statistical techniques must 
be used to analyze the data, taking into account 
whether the data are continuous or discrete.
• Depending on the claims made for the applicability 
of an in vitro test, a range as wide as possible of 
relevant chemicals must be selected to assess 
its utility. The known boundary conditions in 
test performance/interpretation must be taken 
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into account during the selection of the test 
chemicals wherever possible.
• The development and validation of expert 
systems for predicting toxicity and metabolism 
should be encouraged.
CURRENT ALTERNATIVES FOR REPRODUCTIVE 
TOXICITY
There has been a great deal of research and 
debate during the past 20 years concerning the use of 
alternatives to living mammals for testing the potential 
reproductive toxicities of chemical and physical agents 
and mixtures.
Reproduction is a continuous cycle, but for 
purposes of toxicity testing it is broadly divided into 
pregnancy in females (during which period a pre-
natal and post-natal developmental toxicity may be 
induced) and the remainder of the cycle in both 
males and females (during which period fertility 
may be impaired). The majority of research into the 
development of alternative tests has concentrated 
specifically on teratogenicity, which, in turn, is one 
aspect of developmental toxicity. This is, no doubt, 
because of the potential complexity of, and multiple 
targets for, adverse effects on fertility (which include 
effects on sexual behaviour, spermatogenesis, 
oogenesis, hormonal activity or physiological 
response) could interfere with the capacity to fertilise, 
fertilisation itself, or the development of the zygote up 
to and including implantation.
Due to the complexity of the reproductive cycle, 
from gamete maturation to the implantation of the 
early embryo into the maternal uterus, and because 
of the lack of validated alternative tests for most steps 
in the cycle, testing in living animals is the only option 
currently available for assessing the possible effects of 
chemicals on reproduction. It is recommended that 
one or more of the following procedures are included: 
for males, detailed histological examination of the 
testicles and epididymides, semen analysis (15) and/or 
flow cytometric analysis of spermatogenic cell types; 
for females, detailed histological examination of the 
ovary and vaginal cytology (16).
In testing female fertility, alternative approaches 
still exist. Some aspects of female reproductive 
function can be modelled in vitro, and several cellular 
components of the female reproductive organs can 
be maintained in culture. Ovarian somatic cells can 
be maintained in culture, and any adverse effects 
can be assessed by examining cell morphology, 
and by determining cell viability (17) and hormonal 
responsiveness.
According to the assessments of the male fertility, 
several testicular cell types can be maintained in 
culture, either alone or in combination. These include 
Sertoli-germ cell co-cultures, Sertoli cell-enriched 
cultures, germ cell-enriched cultures, Leydig cell 
cultures, and Leydig-Sertoli cell co-cultures. All of 
these systems have been used successfully to study 
specific features of testicular toxicity. Primary cultures 
of testicular cells retain many of the differentiated 
characteristics of their in vivo counterparts, but 
they are inherently variable and generally have only 
a limited lifespan, which necessitates the frequent 
preparation of fresh cultures. The ability to study 
individual cell populations from a heterogeneous 
target organ such as the testis is a powerful tool for 
probing mechanisms of toxicity (18).
The mammalian embryos can be maintained in 
culture for short periods through the phase from 
fertilization to the end of organogenesis. Screening 
systems using mouse and rat embryos have been 
proposed, and the culture of rabbit embryos has 
recently been optimised. At the end of the culture 
period, a number of endpoints can be measured, 
including: effects on the development of the 
visceral yolk sac vascularisation and circulation; 
effects on haematopoiesis, embryonic growth 
and differentiation; dysmorphogenic effects. The 
interpretation of the results obtained takes into 
account the adverse effects on yolk sac development, 
embryonic growth and differentiation, as well as 
specifically on dysmorphogenesis.
However, the system has clear limitations (18):
• It is relatively complex, covers only a part of 
organogenesis, and requires a high level of 
technical skill.
• The test can be costly, and it uses mammalian 
tissue and serum.
• Whether it is justified or not, its use as a 
screening tool should be evaluated by including 
it in a comparative trial with other simpler in vitro 
systems. It is likely that these different systems 
will provide complementary information and 
selection of the appropriate test for a particular 
application should be made on a case study 
basis.
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BIOMARKERS IN TOXICITY TESTING
The term "biomarker" has grown in popularity in 
recent years, and so has its meaning. It ranges from 
exposure measurements and biological indices, which 
support a mechanistic postulate, to clinical markers 
with diagnostic implications. Some meanings of the 
term are given below:
• "Biological markers are indicators signalling 
events in biological systems or samples" and 
"Biological markers are measurements of body 
fluids, cells or tissues that indicate, in biological 
or cellular terms, the presence and magnitude 
of toxicants or of host responses" (19).
• "Biomarkers are cellular, biochemical, or 
molecular alternations, which are measurable 
in biological media such as human tissues, cells 
or fluids" (20).
• "A biomarker is a xenobiotically induced 
variation in cellular or biochemical components 
or processes, structures, or functions, that is 
measurable in a biological system or sample" 
(21).
• "Biomarkers are parameters that putatively 
represent some step along the causal pathway 
between exposure and effect" (22).
• "A biomarker is a parameter, which can be 
evaluated quantitatively, semi-quantitatively or 
qualitatively, and which provides information 
on exposure to a xenobiotic, or on the actual or 
potential effects of that exposure in an individual 
or in a group" (23) etc.
The meaning for which the term biomarker is used 
clearly depends upon the context and this is reflected 
most clearly in the parameters of the database which 
is used as the basis for any search.
The biomarker of exposure could be predictive 
of risk, if sufficient information were available on 
the dose-response relationship. The biomarkers of 
effect cover a range of measurements which may 
be indicative of exposure to a particular agent, 
although their specificity is generally lower than that of 
biomarkers of exposure. Biomarkers of susceptibility
most notably include genetic susceptibility.
The validation of biomarkers is not directly 
comparable with the validation of in vitro tests, but 
must follow the basic principle of demonstrating 
reproducibility, reliability and fitness-for-purpose. The 
actual process will vary, depending on the type of 
biomarker and its intended use. Although biomarkers 
currently cannot replace or reduce the use of animals 
in toxicity testing, future technological developments 
show great promise for making this possible.
The in vitro techniques may play an important 
role in the development of biomarkers of effect, as 
the greater control which is possible in in vitro studies 
facilitates the investigation of mechanisms of toxicity, 
and therefore the identification of key events. The 
mechanistic understanding of the progression of a 
toxic effect is a necessary prerequisite for the use of 
biomarker approaches in the prediction of toxicity. 
It is possible to envisage a natural progression, in 
which a potential biomarker is identified during in
vitro mechanistic studies. The value tested in animal 
models is then incorporated in in vivo testing protocols 
(refinement of animal testing), and is subsequently 
validated for use in in vitro toxicity tests (leading to 
reduction and replacement of animal testing).
At present, it is impossible to reduce, refine and 
replace all animal experiments by applying biomarkers 
in environmental bioassays for toxicological evaluation. 
The acquisition of knowledge, for example, as a result 
of genomic and proteomic technologies, should make 
this feasible in the future (24).
CONCLUSIONS
The in vitro systems are ideally suited for 
investigations of the molecular, cellular and 
physiological mechanisms of chemically induced 
toxicity, which cannot readily be studied in vivo for 
known target organ and target species toxicity studies 
and for answering specific questions about toxic 
effects. The main justification for developing in vitro 
toxicity tests is that they will make toxicology a more 
scientifically-based practice. The understanding of 
the mechanisms by which chemicals cause cell and 
tissue damage, and the reasons for the increased 
susceptibility of certain species, individuals or tissues 
to particular chemicals, will markedly improve our 
ability to predict possible consequences of human 
and/or environmental exposure to them. Perhaps 
the greatest advantage of in vitro toxicity tests is 
that human cells and tissues can be used, thereby 
obviating the need to extrapolate data from laboratory 
animals to man.
The greatest progress in the use of in vitro test 
systems has been achieved in the area of local 
ocular and dermal toxicity and target organ toxicity, 
especially in testing for hepatotoxicity, nephrotoxicity 
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and neurotoxicity. Despite numerous comparisons 
of in vitro cytotoxicity data with rodent LD50 values, 
there has been little progress in the use of in vitro tests 
for predicting overall systemic toxicity, for which the 
need to incorporate data on biokinetics in particular 
is a critical issue.
It is increasingly apparent that the development 
and incorporation of stepwise testing strategies, 
combining experimental data from a range of 
alternative methods (physicochemical techniques, 
quantitative structure-activity relationships - QSAR, 
metabolic and kinetic modelling and in vitro tests), 
provide the most progressive way to predict toxicity, 
reducing at the same time the number of laboratory 
animals used for testing purposes.
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Sažetak
ALTERNATIVNI MODELI ISPITIVANJA TOKSIÈNOSTI KSENOBIOTIKA
Alternativni sustavi ispitivanja toksiènosti na životinjama obuhvaæaju postupke koji ukljuèuju stanice i kulture, 
uporabu dijelova tkiva, toksikokinetièko modeliranje, kao i odnose aktivnosti prema strukturi ksenobiotika. 
Uporaba in vitro sustava (staniènih frakcija, staniènih linija, primarnih staniènih kultura, dijelova tkiva, kulture 
organa itd.) ima široku primjenu u toksikološkim istraživanjima. U posljednjih nekoliko godina fenomen 
apoptoze može se pratiti prema vrlo preciznim unutarstaniènim promjenama te utvrðena programirana smrt 
stanice iskoristiti u uklanjanju takvih stanica iz populacije. In vitro sustavi idealno se rabe u istraživanjima 
molekularnih, staniènih i fizioloških mehanizama toksiènosti izazvanih kemikalijama, dok in vivo studije 
toksiènosti ne mogu dati te odgovore. Glavna potvrda razvoja i praæenja toksiènosti spojeva u in vitro 
testovima jest znanstvena utemeljenost toksikologije. Razvoj i uvoðenje strategija testiranja koje primjenjuju 
kombinaciju eksperimentalnih podataka iz niza alternativnih metoda (fizikalno-kemijske tehnike, QSAR 
tehnike, metabolièko i kinetièko modeliranje) omoguæuje najefikasniju procjenu toksiènosti, kao i istodobno 
smanjenje broja laboratorijskih životinja potrebnih u postupcima testiranja toksiènosti spojeva.
KLJUÈNE RIJEÈI: alternativne metode, biomarkeri, in vitro metode, predviðanje toksièkih rizika, 
provjera valjanosti, testiranje toksiènosti
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